Current management strategies for hepatitis B in the elderly

Drugs and Aging

Volumn 18, Issue 10, 2001, Pages 725-735

  Merle, Philippe ^a,b   Trépo, Christian ^a,b   Zoulim, Fabien ^a,b,c  

^a Lab de Recherche sur les Virus   (France)

^b HÔTEL DIEU   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; LAMIVUDINE; RECOMBINANT ALPHA INTERFERON;

ABDOMINAL PAIN; CANCER SCREENING; CHRONIC HEPATITIS; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; HEADACHE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALAISE; MUSCULOSKELETAL DISEASE; NAUSEA AND VOMITING; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; VACCINATION; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0035212241     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200118100-00002     Document Type: Review

References (4)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45
2. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-56
3. Günther S, Fischer L, Pult I, et al. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999; 52: 25-137
4. Grandjacques C, Pradat P, Stuyver L, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000; 33: 430-9